Document is current
Any future updates will be listed below
-
Authors
Muschitz, C. https://orcid.org/0000-0002-4105-5361
Hummer, M. https://orcid.org/0000-0001-7487-9773
Grillari, J. https://orcid.org/0000-0001-5474-6332
Hlava, A.
Birner, A. H.
Hemetsberger, M. https://orcid.org/0000-0003-1877-6838
Dimai, H. P. https://orcid.org/0000-0001-8155-8265
-
Funding
Funding for this research was provided by:
Amgen GmbH
University of Natural Resources and Life Sciences Vienna
- License Information
-
More Information
Article History
Received: 25 May 2021
Accepted: 7 September 2021
First Online: 8 October 2021
Change Date: 21 February 2022
Change Type: Update
Change Details: The original version was revised due to an update in the funding note.
Declarations
:
: This study was approved by the ethics committee of the medical university of Vienna (ethics committee number: 1216/2021).
: Not applicable.
: Not applicable.
: Christian Muschitz, Michael Hummer, Anton Hlava, Andreas H. Birner, and Hans Peter Dimai have no conflicts of interest to declare. Margit Hemetsberger has received consulting fees from Amgen outside scope of the present work and holds Amgen equity. Johannes Grillari is scientific advisor, co-founder, and shareholder of TAmiRNA GmbH and Evercyte GmbH.
